{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T06:20:55Z","timestamp":1778394055873,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1016\/j.jocn.2005.03.008","type":"journal-article","created":{"date-parts":[[2005,7,19]],"date-time":"2005-07-19T14:39:28Z","timestamp":1121783968000},"page":"739-743","source":"Crossref","is-referenced-by-count":30,"title":["Current approaches to management of depression in Parkinson\u2019s Disease"],"prefix":"10.1016","volume":"12","author":[{"given":"F.J.E.","family":"Vajda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Solinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2005.03.008_bib1","series-title":"Psychiatric and Cognitive disorders in Parkinson\u2019s disease","first-page":"142","year":"2002"},{"key":"10.1016\/j.jocn.2005.03.008_bib2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1176\/appi.neuropsych.13.2.187","article-title":"Prevalence, clinical manifestations, etiology and treatment of depression in Parkinson\u2019s disease","volume":"13","author":"Slaughter","year":"2001","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"Suppl. 5","key":"10.1016\/j.jocn.2005.03.008_bib3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/WNL.56.suppl_5.S1","article-title":"An algorithm for the management of Parkinson\u2019s Disease","volume":"56","author":"Olanow","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2005.03.008_bib4","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1212\/WNL.49.4.1168","article-title":"A survey of antidepressant use in Parkinson\u2019s disease","volume":"49","author":"Hegeman-Richard","year":"1997","journal-title":"Neurology"},{"issue":"Suppl. 6","key":"10.1016\/j.jocn.2005.03.008_bib5","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1212\/WNL.50.6_Suppl_6.S33","article-title":"The management of neuropsychiatric symptoms of Parkinson\u2019s disease","volume":"50","author":"Liberman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2005.03.008_bib6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00019052-200108000-00006","article-title":"Depression in Parkinson\u2019s Disease","volume":"14","author":"Brooks","year":"2001","journal-title":"Current Opinion in Neurology"},{"issue":"3","key":"10.1016\/j.jocn.2005.03.008_bib7","article-title":"Therapies for depression in Parkinson\u2019s disease","author":"Shabnam","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jocn.2005.03.008_bib8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1353-8020(03)00108-1","article-title":"Systematic review of antidepressant therapies in Parkinson\u2019s disease","volume":"10","author":"Chung","year":"2003","journal-title":"Cochrane Database, Parkinsonism and related disorders"},{"key":"10.1016\/j.jocn.2005.03.008_bib9","series-title":"Goodman & Gilman\u2019s: The pharmacological basis of the therapeutics","first-page":"269","article-title":"5HT receptor agonists and antagonists","author":"Sanders-Bush","year":"2001"},{"key":"10.1016\/j.jocn.2005.03.008_bib10","series-title":"Comprehensive textbook of psychiatry","first-page":"2432","article-title":"Selective serotonin reuptake inhibitors","author":"Kelsey","year":"2000"},{"issue":"1","key":"10.1016\/j.jocn.2005.03.008_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00002018-199819010-00002","article-title":"Safety of selegeline (Deprenyl) in the treatment of Parkinson\u2019s disease","volume":"19","author":"Heinonen","year":"1998","journal-title":"Drug saf"},{"key":"10.1016\/j.jocn.2005.03.008_bib12","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1177\/106002809703101208","article-title":"Extrapyramidal reactions and selective serotonin receptor uptake inhibitors","volume":"31","author":"Caley","year":"1997","journal-title":"Ann Psychopharmacother"},{"key":"10.1016\/j.jocn.2005.03.008_bib13","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/026988119801200212","article-title":"SSRI-induced extrapyramidal side effects and akathisia: implications for treatment","volume":"13","author":"Lane","year":"1998","journal-title":"J Psychopharmacology"},{"key":"10.1016\/j.jocn.2005.03.008_bib14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4088\/JCP.v63n0410","article-title":"Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients","volume":"63","author":"Burke","year":"2002","journal-title":"J Clin Psych"},{"key":"10.1016\/j.jocn.2005.03.008_bib15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1212\/WNL.43.1_Part_1.211","article-title":"Increase in Parkinson\u2019s disability after fluoxetine medication","volume":"43","author":"Jansen Steur","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2005.03.008_bib16","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1136\/bmj.320.7245.1287","article-title":"Depression in Parkinson\u2019s disease","volume":"320","author":"Herve","year":"2000","journal-title":"Brit Med J"},{"key":"10.1016\/j.jocn.2005.03.008_bib17","first-page":"162","article-title":"The pros and cons of SSRI antidepressants","volume":"33","author":"Masterton","year":"2003","journal-title":"Coll Physicians Edinb"},{"key":"10.1016\/j.jocn.2005.03.008_bib18","first-page":"7","article-title":"Third generation antidepressants","volume":"43","author":"Olver","year":"2002","journal-title":"Curr Therap"},{"key":"10.1016\/j.jocn.2005.03.008_bib19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/08039489850139049","article-title":"Depression in idiopathic Parkinson\u2019s disease treated with citalopram-A placebo-controlled trial","volume":"52","author":"Wermuth","year":"1998","journal-title":"Nordic Journal of Psychiatry"},{"issue":"1","key":"10.1016\/j.jocn.2005.03.008_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1176\/appi.neuropsych.14.1.31","article-title":"Effects of depression and Parkinson\u2019s disease on cognitive functioning","volume":"14","author":"Norman","year":"2002","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"Suppl. 3","key":"10.1016\/j.jocn.2005.03.008_bib21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/PL00007821","article-title":"Treatment options for depression and psychosis in Parkinson\u2019s Disease","volume":"248","author":"Poewe","year":"2001","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2005.03.008_bib22","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/mds.870120522","article-title":"Sertraline for the treatment of depression in Parkinson\u2019s disease","volume":"12","author":"Hauser","year":"1997","journal-title":"Mov Disord"},{"key":"10.1016\/j.jocn.2005.03.008_bib23","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1212\/WNL.49.4.1168","article-title":"A survey of antidepressant drug use in Parkinson\u2019s disease. (Parkinson study group)","volume":"49","author":"Richard","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2005.03.008_bib24","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1176\/jnp.7.3.281","article-title":"Treatment of depression in Parkinson\u2019s disease: a meta-analysis","volume":"7","author":"Klaassenn","year":"1995","journal-title":"The Journal of Neuropsychiatry and Clinical Neurosciences"},{"issue":"Sep. 14","key":"10.1016\/j.jocn.2005.03.008_bib25","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/(SICI)1099-1166(199909)14:9<711::AID-GPS4>3.0.CO;2-1","article-title":"Depression in patients with PD","author":"Cummings","year":"1999","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.jocn.2005.03.008_bib26","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-0404.1980.tb03028.x","article-title":"Anti-depressive treatment in Parkinson\u2019s disease. A controlled trial of the effect of nortriptyline in patients with Parkinson\u2019s disease treated with L-DOPA","volume":"62","author":"Andersen","year":"1980","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.jocn.2005.03.008_bib27","first-page":"A374","article-title":"Comparison of Fluvoxamine versus Amitriptyline for treatment of depression in Parkinson\u2019s disease","volume":"46","author":"Rabey","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2005.03.008_bib28","first-page":"1010","article-title":"A comparison between low doses of amytriptyline and low doses of fluoxitine used in the control of depression in patients suffering from Parkinson\u2019s disease","volume":"15","author":"Serrano-Duenas","year":"2002","journal-title":"Rev Neurol"},{"key":"10.1016\/j.jocn.2005.03.008_bib29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/(SICI)1520-6394(2000)11:2<58::AID-DA2>3.0.CO;2-H","article-title":"Comparison of pramipexole, fluoxetine, and placebo in patients with major depression","volume":"11","author":"Corrigan","year":"2000","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.jocn.2005.03.008_bib30","doi-asserted-by":"crossref","unstructured":"Rektorova I, Rektor I, Bares M, Dostal V, Ehler E, Fanfrdlova Z, Fiedler J, Klajblova H, Kulist\u2019ak P, Ressner P, Svatova J, Urbanek K, Veliskova J. Pramipexole and pergolide in the treatment of depression in Parkinson\u2019s disease: a national multicentre prospective randomized study. Eur J Neurol 2003 Jul; 10(4): 399\u2013406.","DOI":"10.1046\/j.1468-1331.2003.00612.x"},{"key":"10.1016\/j.jocn.2005.03.008_bib31","doi-asserted-by":"crossref","first-page":"450","DOI":"10.2165\/00003495-199652030-00013","article-title":"Moclobemide: an update of its pharmacological property and therapeutic","volume":"52","author":"Fulton","year":"1996","journal-title":"Drugs"},{"issue":"45","key":"10.1016\/j.jocn.2005.03.008_bib32","first-page":"2157","article-title":"Successful treatment of depression in a Parkinsonian patient with bupropion","volume":"144","author":"Leentjens","year":"2000","journal-title":"Ned Tijdsch Geneeskd"},{"key":"10.1016\/j.jocn.2005.03.008_bib33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1055\/s-2007-979504","article-title":"Psychosis during chronic levodopa therapy triggered by the antidepressant drug mirtazapine","volume":"30","author":"Normann","year":"1997","journal-title":"Pharmacopsychotherapy"},{"key":"10.1016\/j.jocn.2005.03.008_bib34","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4088\/JCP.v63n0405","article-title":"Effects of reboxetine on depression in Parkinson\u2019s disease","volume":"6314","author":"Lemke","year":"2002","journal-title":"J Cli Psychiatry"},{"key":"10.1016\/j.jocn.2005.03.008_bib35","first-page":"790","article-title":"Suicide rates in clinical trials of SSRIs, other antidepressants and placebo: analysis of FDA reports","volume":"160","author":"Khan","year":"2003","journal-title":"M. J. Psychiatr"},{"issue":"Suppl. 1","key":"10.1016\/j.jocn.2005.03.008_bib36","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1212\/WNL.58.suppl_1.S63","article-title":"Clinical features and treatment of depression associated with Parkinson\u2019s disease","volume":"58","author":"Okun","year":"2002","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jocn.2005.03.008_bib37","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1046\/j.1365-2125.2001.01491.x","article-title":"The start of an selective serotonin receptor uptake inhibitor (SSRI) and increase in antiparkinsonian drug treatment in patients on levodopa","volume":"54","author":"van de Vijver","year":"2002","journal-title":"Br. J. Clin. Pharmac."},{"key":"10.1016\/j.jocn.2005.03.008_bib38","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1353-8020(99)00050-4","article-title":"Worsening of Parkinson\u2019s disease by citalopram","volume":"6","author":"Linazasoro","year":"2000","journal-title":"Parkinsonism Related Disorders"},{"key":"10.1016\/j.jocn.2005.03.008_bib39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00002826-200201000-00004","article-title":"The SSRI citalopram improved bradykinesia in patients with Parkinson\u2019s Disease treated with L-dopa","volume":"25","author":"Rampello","year":"2002","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.jocn.2005.03.008_bib40","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1345\/aph.17302","article-title":"Selective serotonin reuptake inhibitor- induced movement disorders. Ann","volume":"32","author":"Gerber","year":"1998","journal-title":"Pharmacother"},{"key":"10.1016\/j.jocn.2005.03.008_bib41","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00002826-200107000-00005","article-title":"SSRIs do not worsen Parkinson\u2019s disease. Evidence from an open-label prospective study","volume":"24","author":"Dell\u2019Agnello","year":"2001","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.jocn.2005.03.008_bib42","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/1531-8257(200009)15:5<986::AID-MDS1034>3.0.CO;2-I","article-title":"Tolerability of paroxetine in the Parkinson\u2019s disease: a prospective study","volume":"15","author":"Tesei","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.jocn.2005.03.008_bib43","first-page":"278","article-title":"Does fluoxetine exacerbate Parkinson\u2019s disease?","volume":"53","author":"Caley","year":"1992","journal-title":"J Clin Psychiatry"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096758680500144X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096758680500144X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T03:41:28Z","timestamp":1551930088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096758680500144X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["S096758680500144X"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2005.03.008","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}